Cargando…
Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma
Multikinase inhibitors (MKIs) such as sorafenib and lenvatinib are first-line treatments for unresectable hepatocellular carcinoma (HCC) and are known to have immunomodulatory effects. However, predictive biomarkers of MKI treatment in HCC patients need to be elucidated. In the present study, thirty...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138027/ https://www.ncbi.nlm.nih.gov/pubmed/37189554 http://dx.doi.org/10.3390/diagnostics13081453 |
_version_ | 1785032609725677568 |
---|---|
author | Han, Ji Won Kim, Ji Hoon Kim, Dong Hyun Jang, Jeong Won Bae, Si Hyun Choi, Jong Young Yoon, Seung Kew Ahn, Jaegyoon Yang, Hyun Sung, Pil Soo |
author_facet | Han, Ji Won Kim, Ji Hoon Kim, Dong Hyun Jang, Jeong Won Bae, Si Hyun Choi, Jong Young Yoon, Seung Kew Ahn, Jaegyoon Yang, Hyun Sung, Pil Soo |
author_sort | Han, Ji Won |
collection | PubMed |
description | Multikinase inhibitors (MKIs) such as sorafenib and lenvatinib are first-line treatments for unresectable hepatocellular carcinoma (HCC) and are known to have immunomodulatory effects. However, predictive biomarkers of MKI treatment in HCC patients need to be elucidated. In the present study, thirty consecutive HCC patients receiving lenvatinib (n = 22) and sorafenib (n = 8) who underwent core-needle biopsy before treatment were enrolled. The associations of CD3, CD68, and programmed cell death-ligand-1 (PD-L1) immunohistochemistry with patient outcomes, including overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), were evaluated. High and low subgroups were determined according to median CD3, CD68, and PD-L1 values. Median CD3 and CD68 counts were 51.0 and 46.0 per 20,000 µm(2), respectively. The median combined positivity score (CPS) of PD-L1 was 2.0. Median OS and PFS were 17.6 and 4.4 months, respectively. ORRs of the total, lenvatinib, and sorafenib groups were 33.3% (10/30), 12.5% (1/8), and 40.9% (9/22), respectively. The high CD68+ group had significantly better PFS than the low CD68+ group. The high PD-L1 group had better PFS than the low subgroup. When we analyzed the lenvatinib subgroup, PFS was also significantly better in the high CD68+ and PD-L1 groups. These findings suggest that high numbers of PD-L1-expressing cells within tumor tissue prior to MKI treatment can serve as a biomarker to predict favorable PFS in HCC patients. |
format | Online Article Text |
id | pubmed-10138027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101380272023-04-28 Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma Han, Ji Won Kim, Ji Hoon Kim, Dong Hyun Jang, Jeong Won Bae, Si Hyun Choi, Jong Young Yoon, Seung Kew Ahn, Jaegyoon Yang, Hyun Sung, Pil Soo Diagnostics (Basel) Article Multikinase inhibitors (MKIs) such as sorafenib and lenvatinib are first-line treatments for unresectable hepatocellular carcinoma (HCC) and are known to have immunomodulatory effects. However, predictive biomarkers of MKI treatment in HCC patients need to be elucidated. In the present study, thirty consecutive HCC patients receiving lenvatinib (n = 22) and sorafenib (n = 8) who underwent core-needle biopsy before treatment were enrolled. The associations of CD3, CD68, and programmed cell death-ligand-1 (PD-L1) immunohistochemistry with patient outcomes, including overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), were evaluated. High and low subgroups were determined according to median CD3, CD68, and PD-L1 values. Median CD3 and CD68 counts were 51.0 and 46.0 per 20,000 µm(2), respectively. The median combined positivity score (CPS) of PD-L1 was 2.0. Median OS and PFS were 17.6 and 4.4 months, respectively. ORRs of the total, lenvatinib, and sorafenib groups were 33.3% (10/30), 12.5% (1/8), and 40.9% (9/22), respectively. The high CD68+ group had significantly better PFS than the low CD68+ group. The high PD-L1 group had better PFS than the low subgroup. When we analyzed the lenvatinib subgroup, PFS was also significantly better in the high CD68+ and PD-L1 groups. These findings suggest that high numbers of PD-L1-expressing cells within tumor tissue prior to MKI treatment can serve as a biomarker to predict favorable PFS in HCC patients. MDPI 2023-04-18 /pmc/articles/PMC10138027/ /pubmed/37189554 http://dx.doi.org/10.3390/diagnostics13081453 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Han, Ji Won Kim, Ji Hoon Kim, Dong Hyun Jang, Jeong Won Bae, Si Hyun Choi, Jong Young Yoon, Seung Kew Ahn, Jaegyoon Yang, Hyun Sung, Pil Soo Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma |
title | Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma |
title_full | Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma |
title_fullStr | Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma |
title_full_unstemmed | Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma |
title_short | Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma |
title_sort | higher number of tumor-infiltrating pd-l1+ cells is related to better response to multikinase inhibitors in hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138027/ https://www.ncbi.nlm.nih.gov/pubmed/37189554 http://dx.doi.org/10.3390/diagnostics13081453 |
work_keys_str_mv | AT hanjiwon highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma AT kimjihoon highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma AT kimdonghyun highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma AT jangjeongwon highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma AT baesihyun highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma AT choijongyoung highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma AT yoonseungkew highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma AT ahnjaegyoon highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma AT yanghyun highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma AT sungpilsoo highernumberoftumorinfiltratingpdl1cellsisrelatedtobetterresponsetomultikinaseinhibitorsinhepatocellularcarcinoma |